Korea’s Celltrion issues $300 million CB

The deal is well-received, particularly by outright investors who see good growth potential for the Kosdaq-listed developer of biologic drugs.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES